Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection

doi:10.3748/wjg.v16.i18.2265

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 18

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5563)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

416

HTML

4711

Figures (1-1)

186

Tables (1-4)

250

Sum=5563

May 14, 2010 (publication date) through Dec 20, 2024

Times Cited of This Article

Times Cited (87)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. May 14, 2010; 16(18): 2265-2271
Published online May 14, 2010. doi: 10.3748/wjg.v16.i18.2265

Table 1 Comparison of baseline features among HBV, HCV, dual HBV and HCV, and non-HBV, non-HCV related hepatocellular carcinoma patients

	HBV n = 63	HCV n = 59	HBV + HCV n = 15	Non-HBV, non-HCV n = 28	P value
Age (yr)¹	55 (46-66)^a^c	66 (57-75)^a^d	60 (50-68)^d	61 (55-67)^c	< 0.001
Sex (M/F)	45/18	41/18	10/5	26/2	0.093
DM (%)	8 (12.7)^a	21 (35.6)^a^e	4 (26.7)	2 (7.1)^e	0.003
BMI (kg/m²)¹	24.3 (22.2-26.8)	23.8 (21.8-26.6)	23.6 (20.9-25.5)	24.5 (23.3-26.7)	0.439
Overweight (%)	24 (38)	22 (37)	4 (27)	10 (36)	0.797
Obesity (%)	4 (6)	5 (8)	1 (7)	2 (7)	0.965
AST (U/L)¹	48 (38-71)^a	72 (39-123)^a^e	72 (47-111)	38 (29-52)^e	0.002
ALT (U/L)¹	45 (34-63)^a	63 (29-100)^a^e	82 (54-117)	27 (21-39)^e	0.011
Child–Pugh class (A/B, C)	47/16	46/13	11/4	23/5	0.857
Platelet (10⁴/μL)¹	16.5 (12.0-25.0)^a	13.2 (8.7-17.1)^a^e	12.7 (7.6-18.1)^f	21.1 (15.3-24.1)^e^f	0.001
AFP (ng/mL)¹	15 (6-525)	28 (7-256)	38 (11-4388)	15 (6-8027)	0.468
Tumor size ( ≤ 3 cm) (%)	14 (22.2)^a	29 (49.2)^a^e	7 (46.7)	5 (17.9)^e	< 0.001
BCLC ( ≤ early stage) (%)	20 (31.7)^a^b	31 (52.5)^a^e^f	9 (60.0)^b	4 (14.3)^e^f	0.001
HOMA-IR	3.5 (2.0-8.6)^a	4.4 (2.9-6.6)^a	3.2 (1.7-10.7)	3.4 (2.0-4.6)	0.108
Insulin (μU/mL)¹	12.8 (8.4-25.0)	14.8 (9.9-21.30)	11.9 (8.1-23.5)	9.7 (7.6-14.8)	0.256
Adiponectin (μg/mL)	4.7 (2.9-8.1)^a^c	7.9 (5.2-11.0)^a^e	8.0 (3.8-10.9)^f	3.7 (2.0-6.0)^c^e^f	0.002

¹Median (interquartile range); P value by one-way ANOVA test or χ² test;

^aP < 0.05 between HBV and HCV;

^bP < 0.05 between HBV and HBV + HCV;

^cP < 0.05 between HBV and non-HBV, non-HCV;

^dP < 0.05 between HCV and HBV + HCV;

^eP < 0.05 between HCV and non-HBV, non-HCV;

^fP < 0.05 between HBV + HCV and non-HBV, non-HCV HCC with LSD post-hoc correction. HBV: Hepatitis B virus; HCV: Hepatitis C virus; DM: Diabetes mellitus; BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; HOMA-IR: Homeostasis model assessment of insulin resistance.

Table 2 Comparison of baseline features, HOMA-IR and adiponectin level among chronic hepatitis, advanced fibrosis and HCC patients with chronic HCV infection

	Chronic hepatitis (F0-2) n = 86	Advanced fibrosis (F3-4) n = 43	Hepatocellular carcinoma n = 59	P value²
Age (yr)¹	53 (45-58)^a^b	56 (49-63)^a^c	66 (57-75)^b^c	< 0.001
Male sex (%)	44 (51)^b	17 (40)^c	41 (69)^b^c	0.008
DM (%)	13 (15)^b	12 (28)	21 (36)^b	0.016
BMI (kg/m²)¹	24.3 (21.8-26.3)	25.0 (22.0-29.4)	23.8 (21.8-26.6)	0.227
AST (U/L)¹	90 (64-122)	114 (87-178)^c	72 (39-123)^c	0.085
ALT (U/L)¹	127 (92-187)^b	140 (102-199)^c	63 (29-100)^b^c	0.001
Platelet (10⁴/μL)¹	20.2 (15.8-22.4)^a^b	13.7 (10.6-17.9)^a	13.2 (8.7-17.1)^b	< 0.001
Sugar (mg/dL)¹	91 (87-101)^b	98 (88-122)^c	114 (94-172)^b^c	< 0.001
Insulin (μU/mL)¹	10.3 (7.7-14.4)^b	11.7 (6.9-15.9)^c	14.8 (9.9-21.3)^b^c	0.003
HOMA-IR¹	3.5 (2.6-4.7)^b	4.1 (2.6-5.9)^c	4.4 (2.9-6.6)^b^c	0.018
Adiponectin (μg/mL)¹	5.0 (3.4-8.4)	5.8 (4.1-9.7)	7.9 (5.2-11.0)	0.222

¹Median (interquartile range);

²P value by one-way ANOVA test or χ² test;

^aP < 0.05 between chronic hepatitis and advanced fibrosis;

^bP < 0.05 between chronic hepatitis and hepatocellular carcinoma;

^cP < 0.05 between advanced fibrosis and hepatocellular carcinoma with LSD post-hoc correction.

Table 3 Univariate and multivariate analysis of factors associated serum adiponectin level in 188 patients with chronic HCV infection

	Univariate		Multivariate
	Coefficient	P value¹	Regression coefficient	SE	P value³
Age	0.388	< 0.001	0.140	0.028	< 0.001
Male sex²	NA	< 0.001	-2.925	0.744	< 0.001
BMI	-0.281	< 0.001	-0.495	0.101	< 0.001
HCC²	NA	0.136	-	-	-
DM²	NA	0.629	-	-	-
Child-Pugh classification	0.107	0.145	-	-	-
AST (U/L)	0.159	0.030	-	-	-
ALT (U/L)	-0.096	0.195	-	-	-
Platelet (10⁴/μL)	-0.198	0.009	-	-	-
Insulin (μU/mL)	-0.179	0.014	-	-	-
HOMA-IR	-0.290	< 0.001	-	-	-

¹P value by Spearman’s test or

²P value by Mann-Whitney U test;

³P value by stepwise linear regression analysis. NA: Not applicable.

Table 4 Stepwise logistic regression analysis of factors associated with HCC

	Comparison	OR	95% CI	P value
All patients
Age	Per 1 year increase	1.124	1.067-1.183	< 0.001
Insulin	Per 1 μU/mL increase	1.585	1.269-1.980	< 0.001
HOMA-IR	Per 1 increase	0.495	0.330-0.743	0.001
DM	Yes vs no	11.601	2.500-53.800	0.002
Sex	Male vs female	3.877	1.282-11.729	0.016
Non-DM patients
Age	Per 1 year increase	1.170	1.075-1.272	< 0.001
Insulin	Per 1 μU/mL increase	2.434	1.555-3.811	< 0.001
HOMA-IR	Per 1 increase	0.158	0.055-0.452	0.001
Sex	Male vs female	6.111	1.310-28.499	0.021

Citation: Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16(18): 2265-2271
URL: https://www.wjgnet.com/1007-9327/full/v16/i18/2265.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i18.2265